Ciliated Cells in Ovarian Cancer Decrease with Increasing Tumor Grade and Disease Progression.
CAPS
FOXJ1
ciliated cells
clear cell
endometrioid
fallopian tube
mucinous
ovarian cancer
secretory cells
serous
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
11 12 2022
11 12 2022
Historique:
received:
24
10
2022
revised:
23
11
2022
accepted:
08
12
2022
entrez:
23
12
2022
pubmed:
24
12
2022
medline:
27
12
2022
Statut:
epublish
Résumé
Ciliated cell markers expressed in epithelial ovarian cancers (EOC) are associated with improved survival. We examined the distribution of cells expressing ciliated cell markers in various EOC histologies and stages. Immunohistochemistry and/or multiplex immunofluorescence were used to determine the expression of FOXJ1 and/or CAPS (ciliated cell markers) in tissue microarrays including 4 normal fallopian tubes, 6 normal endometria, 16 cystadenomas, 25 borderline tumors, 21 low-grade carcinomas, and 118 high-grade carcinomas (HGSOC) (46 serous, 29 endometrioid, 30 clear cell, 13 mucinous). CAPS+ cells were observed in normal fallopian tubes and endometria and in ~85% of serous benign and borderline tumors and low-grade carcinomas but only in <40% of HGSOC. mRNA data from an independent cohort showed higher FOXJ1 and CAPS expression in serous borderline tumors and low-grade carcinomas compared to HGSOC. In HGSOC, ciliated cell-positive markers were observed in 52% primary tumors compared to 26% of patient-matched synchronous metastases, and 24% metachronous metastases (
Identifiants
pubmed: 36552773
pii: cells11244009
doi: 10.3390/cells11244009
pmc: PMC9776429
pii:
doi:
Types de publication
Journal Article
Research Support, U.S. Gov't, Non-P.H.S.
Research Support, Non-U.S. Gov't
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : BLRD VA
ID : I01 BX004974
Pays : United States
Organisme : NCATS NIH HHS
ID : UL1 TR001881
Pays : United States
Organisme : NIH HHS
ID : UL1TR00188
Pays : United States
Références
Nat Rev Cancer. 2015 Nov;15(11):668-79
pubmed: 26493647
Appl Immunohistochem Mol Morphol. 2008 Oct;16(5):453-8
pubmed: 18665037
Exp Biol Med (Maywood). 2014 Jan;239(1):24-32
pubmed: 24186266
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S5-8
pubmed: 25341581
Oncogene. 2016 Jan 7;35(1):59-68
pubmed: 25798842
Clin Cancer Res. 2022 Dec 15;28(24):5383-5395
pubmed: 36222710
J Pathol. 2017 Sep;243(1):26-36
pubmed: 28678427
N Engl J Med. 2019 Mar 28;380(13):1256-1266
pubmed: 30917260
J Pathol. 2007 Jan;211(1):26-35
pubmed: 17117391
Clin Cancer Res. 2021 Mar 1;27(5):1570-1579
pubmed: 33446563
J Clin Pathol. 1999 May;52(5):355-7
pubmed: 10560355
Cancer. 1989 Jul 1;64(1):110-5
pubmed: 2731107
Oncotarget. 2015 Dec 22;6(41):43843-52
pubmed: 26549805
Histopathology. 2018 Apr;72(5):766-776
pubmed: 29197096
CA Cancer J Clin. 2022 Jan;72(1):7-33
pubmed: 35020204
Pathol Res Pract. 2017 Apr;213(4):305-309
pubmed: 28238382
Br J Cancer. 2022 Nov 2;:
pubmed: 36323878
Clin Med Res. 2007 Mar;5(1):35-44
pubmed: 17456833
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S14-9
pubmed: 25341574
Endocr Relat Cancer. 2011 Sep 20;18(5):627-42
pubmed: 21813729
Diagnostics (Basel). 2020 Jan 19;10(1):
pubmed: 31963927
Hum Reprod Update. 2006 Jul-Aug;12(4):363-72
pubmed: 16565155
Front Oncol. 2022 Mar 21;12:853755
pubmed: 35387127
Am J Pathol. 2016 Apr;186(4):733-47
pubmed: 27012190
Am J Cancer Res. 2020 Nov 01;10(11):3815-3827
pubmed: 33294269
Int J Mol Sci. 2018 Aug 24;19(9):
pubmed: 30149579
Int J Gynecol Pathol. 2015 Jan;34(1):3-8
pubmed: 25473746
Gynecol Oncol. 2017 Jun;145(3):595-602
pubmed: 28237618
Oncogene. 2010 Feb 25;29(8):1103-13
pubmed: 19935705
Nat Commun. 2019 Sep 2;10(1):3935
pubmed: 31477716
Am J Surg Pathol. 2011 Dec;35(12):1759-65
pubmed: 22089527